Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
Paresh Dandona(Jacobs Institute), Bertrand Cariou(Institut du Thorax), R Dumas, Steven C. Griffen(Io Therapeutics (United States)), Anna Maria Langkilde(AstraZeneca (Sweden)), Christoph Schnack, Francis Duyck, Johannes Ruige, Moshe Phillip(Schneider Children's Medical Center), Diethelm Tschöpe(Heart and Diabetes Center North Rhine-Westphalia), Vincent Woo, Rudolf Prager, Jens Meldgaard Bruun(Steno Diabetes Centers), Jyrki Taurio, Samy Hadjadj(Université de Poitiers), André Scheen(University of Liège), John Xu(AstraZeneca (United States)), Chris Vercammen, Kirsi H. Pietiläinen(University of Helsinki), Lars Hansen(Novo Nordisk (Denmark)), Frank Nobels(Rotterdam University of Applied Sciences), Juha Saltevo(University of Helsinki), Claire Morbey, David N. O’Neal(Baker Heart and Diabetes Institute), Chantal Mathieu(KU Leuven), Troels Krarup Hansen(Steno Diabetes Centers), Jan Erik Henriksen(State University of New York), Bertram Hoelzl, Fredrik Thorén(AstraZeneca (Sweden)), Joseph Proietto, Bruno Guerci(Inserm), Ursula Hanusch, Bruno St-Pierre, Evelyn Fliesser-Goerzer, Thomas G. Elliott, Christoph Ebenbichler(Innsbruck Medical University), Jorma Strand, Aina S. Lihn, Irene Hramiak(St Joseph's Health Care), Roger Chen(UNSW Sydney), Jeppe Gram, Timo T. Valle, Sakari Nieminen, Luc Van Gaal(Inserm), Mark Forbes, Anton Luger(Medical University of Vienna), Alexia Pape, Stephen Stranks, Naresh Aggarwal
Cited by 295
Related Papers
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
|Diabetes Care|2019|3.8k
A Genome-Wide Association Study of Type 2 Diabetes in Finns Detects Multiple Susceptibility Variants
|Science|2007|2.8k
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2022|2.6k
International Consensus on Use of Continuous Glucose Monitoring
|Diabetes Care|2017|2k